HER2 breast cancer therapies: a review
Conleth G Murphy, Shanu ModiBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been...
Main Authors: | Conleth G Murphy, Shanu Modi |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-06-01
|
Series: | Biologics : Targets & Therapy |
Online Access: | http://www.dovepress.com/her2-breast-cancer-therapies-a-review-a3250 |
Similar Items
-
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
by: Emanuela Ferraro, et al.
Published: (2021-08-01) -
Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01) -
Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
by: Stenehjem DD, et al.
Published: (2014-10-01) -
Predictive value of HER-2 in breast cancer: Endocrine therapy
by: Šušnjar Snežana, et al.
Published: (2002-01-01) -
Present and future of breast cancer anti-Her-2-therapy
by: V. P. Letyagin
Published: (2014-07-01)